A phase II study reported an overall survival outcome for CIMAvax-EGF plus nivolumab in previously treated advanced non-small-cell lung cancer, reporting 11.9 months median OS. The trial also highlighted a stronger benefit signal in EGFR/ALK/KRAS wild-type tumors. CIMAvax-EGF is designed to generate immune responses against epidermal growth factor signaling, while nivolumab provides PD-1 blockade. In the provided brief, the survival figure and subgroup observation are the primary datapoints discussed. The results add to the expanding set of combinations aiming to improve outcomes after standard therapies, with tumor biomarker selection emerging as the key discussion point for next-stage development.